Treatment of Scalp Psoriasis

Topical Corticosteroids and Vehicle Formulations

Vehicle formulations specifically designed for scalp application, such as solutions, foams, and shampoos, improve adherence and efficacy compared to creams or ointments, according to the American Academy of Dermatology 1, 2

Vitamin D Analogues

Calcipotriene foam is effective for scalp psoriasis, with 40.9% of patients achieving clear or almost clear status after 8 weeks, as recommended by the American Academy of Dermatology 3, 4
Vitamin D analogues show efficacy at 8 weeks but not at 4 weeks, which should be considered when planning treatment duration, based on guidelines from the American Academy of Dermatology 4
Calcipotriene foam and calcipotriene plus betamethasone dipropionate gel for 4-12 weeks are safe and effective for mild to moderate scalp psoriasis, according to the American Academy of Dermatology 3
UVA radiation can decrease the concentration of calcipotriene on the skin, so it should be applied after phototherapy to avoid inactivation, as suggested by the American Academy of Dermatology 3

Combination Therapy

Combination of calcipotriene with potent corticosteroids is more effective than either agent alone for treating psoriasis, based on recommendations from the American Academy of Dermatology 4
A 52-week study showed 69-74% of patients treated with calcipotriene 0.005% plus betamethasone 0.064% once or twice daily achieved clear or almost clear status, as reported by the American Academy of Dermatology 4
No serious adverse events, including striae or hypothalamic-pituitary-adrenal axis suppression, were observed over the 52-week treatment period with this combination, according to the American Academy of Dermatology 4

Initial Assessment and Treatment Algorithm

Initial assessment should evaluate the severity of scalp psoriasis, as recommended by the American Academy of Dermatology 5

Important Considerations

Poor adherence to treatment regimens is common, often due to inconvenience, time constraints, and frustration with messy formulations, according to the American Academy of Dermatology 2
For women of childbearing potential, most topical psoriasis medications are pregnancy category C, and tazarotene is category X, as noted by the American Academy of Dermatology 2

Treatment of Scalp Psoriasis with Topical Corticosteroids

First-Line Treatment: Topical Corticosteroids

The American Academy of Dermatology recommends topical corticosteroids as the first-line treatment for scalp psoriasis, with class 1-7 corticosteroids recommended for initial and maintenance treatment for a minimum of up to 4 weeks, with a strength of recommendation A and strong evidence (Level I) 6, 7
Topical corticosteroids have efficacy rates varying widely among different potency classes, ranging from 41% to 92% 8
For patients with severe scalp psoriasis, 83% treated with fluocinolone acetonide 0.01% oil (class VI) showed good or better improvement compared to 36% with vehicle, and 74% of patients with scalp psoriasis treated with halcinonide solution (class II) achieved excellent or good response compared to 45% with vehicle 9, 10
72% of patients with moderate to severe scalp psoriasis treated with betamethasone valerate foam (class IV) showed improvement compared to 47% with placebo 11

Dosing and Duration

Topical corticosteroids can be used 1-2 times daily, with treatment duration of up to 4 weeks recommended for initial therapy, and longer use (>12 weeks) can be considered under careful physician supervision (Strength of recommendation C, Level of evidence III) 6, 7, 12
Gradual reduction in frequency after clinical improvement is recommended to prevent rebound, and intralesional corticosteroids can be used for localized non-responding or very thick lesions, with triamcinolone acetonide up to 20 mg/mL every 3-4 weeks 6, 9

Potential Adverse Effects and Monitoring

Most common local adverse effects include burning and stinging sensation, and other potential adverse effects include skin atrophy, striae, folliculitis, telangiectasia, and purpura, with monitoring important when using high-potency corticosteroids for extended periods 6, 9

Treatment Algorithm

For mild to moderate scalp psoriasis, class 3-7 corticosteroids are recommended, and for moderate to severe scalp psoriasis, class 1-2 (high-potency) corticosteroids are recommended 6, 8, 10
For long-term management, gradually reduce frequency of corticosteroid application, and consider combination with vitamin D3 derivatives or coal tar-containing shampoo 6, 9

Treatment of Scalp Psoriasis

First-Line Treatment Options

The American Academy of Dermatology recommends calcipotriene plus betamethasone dipropionate gel or foam as an equally effective first-line option for scalp psoriasis, achieving 69-74% clear or almost clear status in a 52-week study, with no serious adverse events observed over 52 weeks of treatment 13
The combination of calcipotriene and betamethasone dipropionate is more effective than either agent alone, with 69-74% of patients showing clear or almost clear status, compared to 27% with vehicle 13

Systemic Therapy Considerations

The European League Against Rheumatism considers scalp psoriasis a "vulnerable area" that may warrant systemic therapy if topical treatment fails, particularly when there is symptomatic disease or more than minimal impact on quality of life 14, 15

Treatment of Scalp Psoriasis with Topical and Systemic Therapies

Patient Preferences and Vehicle Selection

African American patients often prefer oil-based preparations for scalp compatibility with routine hair care, and the most appropriate vehicle is the one the patient will actually use consistently, according to the American Academy of Dermatology 16

Systemic Treatment Options

Narrowband UVB phototherapy, a well-tolerated and cost-effective option, can be considered for systemic therapy, as recommended by the European League Against Rheumatism 16
PUVA photochemotherapy is more efficacious than NB-UVB for thick lesions and darker skin due to better UVA penetration, as noted by the American Academy of Dermatology 16
Methotrexate is effective for severe, recalcitrant, disabling psoriasis not responsive to other therapies, but is contraindicated with significant alcohol intake or liver disease, according to the American Academy of Dermatology 16
Acitretin can be used as monotherapy or combined with NB-UVB, particularly suitable for postmenopausal women, but is teratogenic and contraindicated in women of childbearing potential, as recommended by the American Academy of Dermatology 16
Biologic agents, such as anti-IL-17 and anti-IL-23, can be considered for severe cases, but TNF-alfa inhibitors are contraindicated in patients with demyelinating diseases like multiple sclerosis, according to the American Academy of Dermatology 16

Systemic Therapy Indications and Biologic Options for Scalp Psoriasis

Indication for Systemic Therapy

Scalp psoriasis is classified as a “vulnerable area” that warrants escalation to systemic therapy when topical treatment fails, especially when disease is symptomatic or has more than minimal impact on quality of life. 17

Biologic Therapies

Infliximab (American Academy of Dermatology)

Infliximab is recommended as monotherapy for moderate‑to‑severe scalp psoriasis (Strength of Recommendation B); the dosing schedule is 5 mg/kg intravenous infusions at weeks 0, 2, 6, then every 8 weeks thereafter. [18][19]

Etanercept (American Academy of Dermatology)

Etanercept is supported by Level I‑III evidence for scalp psoriasis; initiate at 50 mg twice weekly for 12 weeks, then continue with 50 mg weekly as maintenance therapy. [18][19]

Guideline Recommendations for Topical Management of Scalp Dermatologic Conditions

First‑Line Topical Corticosteroid Selection

Treatment Duration, Frequency, and Supervision

Safety Precautions and Monitoring

Combination Therapy with Vitamin D Analogue

Guidelines for Escalation and Systemic Treatment of Scalp Psoriasis

Indications for Initiating Systemic Therapy

Systemic therapy should be considered when topical treatment fails and the patient exhibits any of the following: symptomatic disease (e.g., pain, bleeding, itching), a quality‑of‑life impact beyond minimal, inadequate response to localized therapy, involvement of more than 5 % of body surface area, or functional disability attributable to psoriasis. 23

Preferred Systemic Treatment Options

Phototherapy

PUVA (psoralen + UVA) is regarded as the least toxic systemic agent and is generally recommended as the first‑line systemic treatment for extensive scalp psoriasis. 24

Conventional Systemic Agents

Cyclosporin therapy requires regular monitoring of blood pressure and serum creatinine to detect potential nephrotoxicity and hypertension. 24

Safety and Contraindications

Pregnancy Considerations

All systemic agents are absolutely contraindicated during pregnancy; clinicians must emphasize the necessity of reliable contraception before initiating any systemic therapy. 24

All statements are supported by the cited references and reflect the strength of evidence where reported.